Lobe Sciences Ltd.
LOBE
CNSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | 219.50% | -46.11% |
| Gross Profit | -- | -- | -- | -120.62% | -101.46% |
| SG&A Expenses | 98.81% | 69.29% | 94.23% | 1.71% | -23.57% |
| Depreciation & Amortization | -- | -- | -- | -100.00% | -71.64% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.15% | 119.44% | 80.30% | -19.94% | -38.34% |
| Operating Income | -198.15% | -119.44% | -91.78% | -10.47% | 14.96% |
| Income Before Tax | -49.14% | -14.00% | -8.90% | -91.29% | -74.27% |
| Income Tax Expenses | -- | -- | -- | -84.33% | -84.33% |
| Earnings from Continuing Operations | -48.10% | -13.19% | -8.09% | -79.04% | -62.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.09% | 4.22% | 1.60% | -74.18% | -62.78% |
| EBIT | -198.15% | -119.44% | -91.78% | -10.47% | 14.96% |
| EBITDA | -30.11% | -58.52% | -95.69% | -12.86% | 14.35% |
| EPS Basic | -308.71% | -300.66% | -296.99% | -789.55% | -817.01% |
| Normalized Basic EPS | -1,218.86% | -1,159.84% | -1,122.49% | -200.00% | -199.15% |
| EPS Diluted | -308.71% | -300.66% | -296.99% | -789.55% | -817.01% |
| Normalized Diluted EPS | -1,218.86% | -1,159.84% | -1,122.49% | -200.00% | -199.15% |
| Average Basic Shares Outstanding | 50.32% | 70.90% | 94.82% | 31.09% | 12.88% |
| Average Diluted Shares Outstanding | 50.32% | 70.90% | 94.82% | 31.09% | 12.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |